BMO Capital downgrades Biogen Idec (Nasdaq: BIIB) from Outperform to Market Perform.

The downgrade follows Biogen's Q2 results ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE